急性淋巴细胞白血病患者再生骨髓中B细胞前体的详细免疫表型分析:对微小残留病检测的启示
该研究采用基于EuroFlow的8色流式细胞术和新型分析工具,首先表征健康儿童骨髓中正常B细胞前体(BCP)的免疫表型成熟过程,建立包含过渡阶段的连续多参数通路;随后以此通路为参考,表征B细胞前体急性淋巴细胞白血病(BCP-ALL)患儿治疗后再生骨髓中BCP的免疫表型成熟。研究发现再生骨髓中存在CD34低表达或暗淡的pre-B-I细胞,在pre-B-I亚群中占11-85%,而健康对照骨髓中 hardly 存在(pre-B-I亚群中占9-13%;P=0.0037)。部分BCP-ALL诊断时的免疫表型(23%)与CD34暗淡pre-B-I细胞重叠,提示这些新发现的CD34暗淡pre-B-I细胞可能被误认为残留BCP-ALL细胞,导致假阳性MRD结果,因此再生骨髓应作为流式MRD检测的参考框架。
要点
- 再生骨髓中CD34暗淡pre-B-I细胞在pre-B-I亚群中占11-85%,健康对照骨髓中占9-13%(P=0.0037)。
- 23%的BCP-ALL诊断免疫表型与CD34暗淡pre-B-I细胞重叠,可能导致假阳性MRD结果。
- 流式细胞术MRD检测应以再生骨髓为参考框架,避免将CD34暗淡pre-B-I细胞误判为残留白血病细胞。
核心结论
- 新发现的CD34暗淡pre-B-I细胞可能被误认为残留BCP-ALL细胞,潜在导致假阳性MRD结果;再生骨髓中CD34暗淡pre-B-I细胞相对丰富,应作为流式细胞术MRD检测的参考框架。
研究设计与样本
- 研究采用基于EuroFlow的8色流式细胞术和新型分析工具,首先表征健康儿童骨髓中正常B细胞前体的免疫表型成熟,建立连续多参数通路;随后以此通路为参考,表征BCP-ALL治疗后儿童再生骨髓中B细胞前体的免疫表型成熟。
主要发现
- 再生骨髓中CD34低表达或暗淡的pre-B-I细胞在pre-B-I亚群中占11-85%,健康对照骨髓中 hardly 存在(pre-B-I亚群中占9-13%;P=0.0037)。
- 部分BCP-ALL诊断免疫表型(23%)与CD34暗淡pre-B-I细胞重叠。
关键数值与推荐
- CD34暗淡pre-B-I细胞在再生骨髓pre-B-I亚群中占11-85%,健康对照骨髓pre-B-I亚群中占9-13%(P=0.0037)。
- 23%的BCP-ALL诊断免疫表型与CD34暗淡pre-B-I细胞重叠。
临床怎么用
- 作者认为,再生骨髓中CD34暗淡pre-B-I细胞相对丰富,应作为流式细胞术MRD检测的参考框架。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Flow cytometric detection of minimal residual disease (MRD) in children with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) requires immunophenotypic discrimination between residual leukaemic cells and B-cell precursors (BCPs) which regenerate during therapy intervals. In this study, EuroFlow-based 8-colour flow cytometry and innovative analysis tools were used to first characterize the immunophenotypic maturation of normal BCPs in bone marrow (BM) from healthy children, resulting in a continuous multiparametric pathway including transition stages. This pathway was subsequently used as a reference to characterize the immunophenotypic maturation of regenerating BCPs in BM from children treated for BCP-ALL. We identified pre-B-I cells that expressed low or dim CD34 levels, in contrast to the classical CD34high pre-B-I cell immunophenotype. These CD34-dim pre-B-I cells were relatively abundant in regenerating BM (11-85% within pre-B-I subset), while hardly present in healthy control BM (9-13% within pre-B-I subset; P = 0·0037). Furthermore, we showed that some of the BCP-ALL diagnosis immunophenotypes (23%) overlapped with CD34-dim pre-B-I cells. Our results indicate that newly identified CD34-dim pre-B-I cells can be mistaken for residual BCP-ALL cells, potentially resulting in false-positive MRD outcomes. Therefore, regenerating BM, in which CD34-dim pre-B-I cells are relatively abundant, should be used as reference frame in flow cytometric MRD measurements.
引用
- Theunissen PMJ, Sedek L, De Haas V, et al. Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection. Br J Haematol. 2017. PMID: 28419441. doi:10.1111/bjh.14682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。